Quest for the right Drug
אדקס 200 ADEX 200 (IBUPROFEN)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
קפליות : CAPLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Interactions : אינטראקציות
4.5 Interaction with other medicinal products and other forms of interaction Ibuprofen should be avoided in combination with: Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is not generally recommended because of the potential increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelets aggregation when they are dosed concomitantly. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional use (see section 5.1). Other NSAIDs including cyclooxygenase-2 selective inhibitors: avoid concomitant use of two or more NSAIDs as this may increase the risk of adverse effects (see section 4.4). Ibuprofen (like other NSAIDs) should be used with caution in combination with: Anticoagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4). It is considered unsafe to take NSAIDs in combination with warfarin or heparin unless under direct medical supervision. Antihypertensives (ACE inhibitors and Angiotensin II Antagonists) and diuretics: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking ibuprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter. Diuretics can increase the risk of nephrotoxicity of NSAIDs. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycoside levels. Aminoglycosides: reduction in renal function in susceptible individuals, decreased elimination of aminoglycoside and increased plasma concentrations. Lithium: decreased elimination of lithium. Methotrexate: decreased elimination of methotrexate. Ciclosporin: increased risk of nephrotoxicity with NSAIDs. Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone. Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus. Probenecid: reduction in metabolism and elimination of NSAID and metabolites. Oral hypoglycaemic agents: Inhibition of metabolism of sulfonylurea drugs, prolonged half-life and increase risk of hypoglycaemia. Zidovudine: Increased risk of haematological toxicity when NSAIDs are given with Zidovudine. There is evidence of an increased risk of haemarthrosis and haematoma in HIV (+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen. Quinolone antibiotics: Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.
שימוש לפי פנקס קופ''ח כללית 1994
Rheumatoid arthritis & osteoarthritis, mild to moderate pain, dysmenorrhea
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
עלון מידע לצרכן
22.05.13 - עלון לצרכן 16.10.18 - עלון לצרכן אנגלית 21.10.18 - עלון לצרכן אנגלית 16.10.18 - עלון לצרכן עברית 21.10.18 - עלון לצרכן עברית 16.10.18 - עלון לצרכן ערבית 21.10.18 - עלון לצרכן ערבית 21.10.18 - עלון לצרכן 15.08.23 - עלון לצרכן עברית 16.08.23 - עלון לצרכן עברית 04.04.24 - עלון לצרכן אנגלית 04.04.24 - עלון לצרכן עברית 04.04.24 - עלון לצרכן ערבית 09.05.24 - עלון לצרכן עברית 09.05.24 - עלון לצרכן 12.05.24 - עלון לצרכן אנגלית 12.05.24 - עלון לצרכן ערבית 01.07.18 - החמרה לעלון 16.10.18 - החמרה לעלון 21.10.18 - החמרה לעלון 22.05.13 - החמרה לעלון 15.08.23 - החמרה לעלוןלתרופה במאגר משרד הבריאות
אדקס 200
